Global pharmaceutical company Allergan has received a ‘positive opinion’ from the Swedish Medical Products Agency (MPA) for BELKYRA.
BELKYRA (deoxycholic acid) – also known as KYBELLA in the US – is aimed at treating submental fullness. It will be the first prescription medicine to be licensed in Europe for the treatment of a double-chin, when the presence of submental fat has a psychological impact on the patient.
"We are delighted to receive the ‘positive opinion’ from the MPA for BELKYRA, which provides men and women who are bothered by submental fullness with a new minimally-invasive treatment option," said David Nicholson, chief R&D officer at Allergan. "Because of the extensive evidence behind the product, we see BELKYRA as a breakthrough treatment that will complement other aesthetic treatments."
According to the American Society for Dermatologic Surgery in 2015, fat under the chin/neck topped the list of most troublesome conditions for patients, with 67% reporting being concerned or bothered about the condition.